A Phase 1-2 dose-escalation and expansion study of ST101 in patients with advanced unresectable and metastatic solid tumors
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Sapience Therapeutics Inc.
Start Date
January 20, 2022
End Date
February 15, 2027
Administered By
Duke Cancer Institute
Awarded By
Sapience Therapeutics Inc.
Start Date
January 20, 2022
End Date
February 15, 2027